Private review without marketplace signaling.
TSCIP absorbs part of the upstream screening burden while preserving buyer confidentiality and focusing attention on the uncertainty that matters to a strategic decision.
Curated opportunities, not a broad asset feed.
TSCIP is designed to reduce upstream screening burden. Clinical-stage oncology assets are selected for coverage and framed around the strategic question that remains unresolved, rather than presented only as a seller narrative.
Private by default
Buyer searches, reviews, saves, passes and private decision requirements are not disclosed to asset owners. Buyer identity is released only with explicit consent.
What a strategic buyer can evaluate.
Clinical signal
What the current evidence establishes—and what it does not.
Strategic uncertainty
The specific issue preventing the asset from crossing a decision threshold.
Evidence path
A bounded way to test whether the uncertainty is solvable.
Backbone context
Where relevant, the asset can be considered against existing internal or external therapeutic backbones without publishing TSCIP's counterparty-ranking logic.
Transaction readiness
A concise view of what would need to be true before a deeper diligence or transaction process is rational.
Permissioned engagement
When there is genuine interest, TSCIP can support an owner-authorized path to direct engagement.
No owner-side buyer surveillance.
The confidentiality boundary is intentional. It lets strategic teams explore covered assets without creating a marketplace signal and lets TSCIP learn from decision requirements without turning private buyer behavior into a sales dashboard.
Interested in reviewing covered opportunities?
TSCIP can discuss the public operating model and establish a confidential review path appropriate to the organization.